<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778842</url>
  </required_header>
  <id_info>
    <org_study_id>RESET ELDERLY</org_study_id>
    <nct_id>NCT01778842</nct_id>
  </id_info>
  <brief_title>Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome</brief_title>
  <acronym>RESET ELDERLY</acronym>
  <official_title>PhaRmacodynamic Effect of Antiplatelet Agents in Elderly Patients: Standard Clopidogrel Versus prasugrEl Low Dose Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gennaro Sardella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The elderly represent a growing segment of the coronary population treated by dual
      antiplatelet therapy for percutaneous coronary intervention (PCI). These patients bear a
      higher risk of both ischemic events and bleeding complications than younger patients, with a
      subsequently higher rate of mortality.Recentprogress in antithrombotic treatment demonstrated
      the efficacy of adding a P2Y12 receptor antagonist to low-dose aspirin. Whether this benefit
      is also present in the elderly remains a debated issue due to the lack of specific data in
      this sub-population. The present study was realized to provide specific data on platelet
      response to clopidogrel, standard dose (75 mg) or prasugrel 5 mg in elderly patients (≥75
      years old) whereas the superiority in PR response of the latter should allows the Prasugrel
      therapy in elderly patients with the better clinical efficacy and therapeutical safety
      already showed compared with Clopidogrel.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>superiority of prasugrel low dose</measure>
    <time_frame>30 days</time_frame>
    <description>The primary aim will be to investigate the antiplatelet effect of half dose of prasugrel (5 mg) versus standard dose of clopidogrel in patients with acute coronary syndrome and coronary diseases, treated with percutaneous coronary intervention and stent implantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Bleeding (major, minor, or minimal according to the TIMI study criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac events</measure>
    <time_frame>12 months</time_frame>
    <description>major adverse cardiac events (cardiovascular death, myocardial infarction, and stroke) will be evaluated during the all period of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Prasugrel low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be randomized to this intervention will receive prasugrel 5 mg and after 15 days and 30 days we will control the responsivness of the study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel standard dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be randomized to this intervention will receive clopidogrel 75 mg and after 15 days and 30 days we will control the responsivness of the study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.</description>
    <arm_group_label>Clopidogrel standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.</description>
    <arm_group_label>Prasugrel low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute coronary syndrome

          -  PCI with stent implantation

          -  clopidogrel responsiveness

          -  &gt; 75 years of age.

        Exclusion Criteria:

          -  history of bleeding diathesis

          -  chronic oral anticoagulation treatment

          -  contraindications to antiplatelet therapy

          -  PCI or coronary artery bypass grafting (CABG) &lt; 3 months

          -  hemodynamic instability

          -  platelet count &lt; 100,000/μl

          -  hematocrit &lt; 30%

          -  creatinine clearance &lt; 25 ml/min

          -  Patients with a history of stroke

          -  other contraindication for prasugrel administration

          -  patients weighing &lt; 60 kg

          -  high on treatment platelet reactivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gennaro Sardella, MD</last_name>
    <phone>+390649979035</phone>
    <email>rino.sardella@uniroma1.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept.of Cardiovascular Sciences,Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>000161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rocco Stio, MD</last_name>
      <phone>+300649979046</phone>
      <email>rocco.stio@libero.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Gennaro Sardella</investigator_full_name>
    <investigator_title>Associate Professor in Cardiology</investigator_title>
  </responsible_party>
  <keyword>antiplatelet effect</keyword>
  <keyword>prasugrel</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

